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Background: One third of the world’s population is thought to have latent tuberculosis infection (LTBI) with the
potential for subsequent reactivation of disease. To better characterize this important population, studies comparing
Tuberculin Skin Test (TST) and the new interferon-γ release assays including QuantiFERONW-TB Gold In-Tube
(QFT-GIT) have been conducted in different parts of the world, but most of these have been in countries with a
low incidence of tuberculosis (TB). The aim of this study was therefore to evaluate the use of QFT-GIT assay as
compared with TST in the diagnosis of LTBI in Ethiopia, a country with a high burden of TB and routine BCG
vaccination at birth.
Methods: Healthy medical and paramedical male students at the Faculty of Medicine, Addis Ababa University,
Ethiopia were enrolled into the study from December 2008 to February 2009. The TST and QFTG-IT assay were
performed using standard methods.
Results: The mean age of the study participants was 20.9 years. From a total of 107 study participants,
46.7% (95%CI: 37.0% to 56.6%) had a positive TST result (TST≥10 mm), 43.9% (95%CI: 34.3% to 53.9%) had a positive
QFT-GIT assay result and 44.9% (95%CI: 35.2% to 54.8%) had BCG scar. There was strong agreement between
TST (TST ≥10mm) and QFT-GIT assay (Kappa = 0.83, p value = 0.000).
Conclusion: The TST and QFT-GIT assay show similar efficacy for the diagnosis of LTBI in healthy young adults
residing in Ethiopia, a country with high TB incidence.
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Tuberculosis (TB) is one of the leading causes of mor-
bidity due to infectious disease, and its ability to estab-
lish latent infection compounds the difficulty of
controlling the spread of infection. The primary cause of
TB in humans is Mycobacterium tuberculosis (MTB)
which together with M. bovis, M. bovis Bacille Calmette-
Guérin (BCG), M. africanum, M. microti, and M. canetti
makes up the M. tuberculosis complex (MTBC) [1].* Correspondence: fitayehu@yahoo.com
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reproduction in any medium, provided the orExposure to a person with active TB, leading to infec-
tion, can result in one of the three outcomes [2]. The in-
nate immune system can rapidly eliminate the tubercle
bacilli, leaving no evidence of exposure to TB; the tuber-
cle bacilli can escape immune control and disseminate,
causing so-called primary TB; or bacterial growth can be
controlled but some bacilli survive and persist leading to
latent tuberculosis infection (LTBI). The last two possi-
bilities exist in a dynamic equilibrium, with episodes of
disease and long periods of asymptomatic latent infec-
tion, or progressive and fatal disease both being possible
outcomes.
An estimated 2 billion people worldwide have LTBI
and may subsequently have reactivation of dormantl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of study participants (n =107),








First year 43 (40.2)
Second year 47 (43.9)
Third year 17 (15.9)
Place of birth (Region)
Addis Ababa 17 (15.9)
Amhara 30 (28.0)
Oromia 29 (27.1)






Claimed to have habit of Khat3 Consumption 9 (8.4)
Claimed to have habit of Cigarette Smoking 2 (1.9)
1 Midwifery, Radiography, Medicine, Dentistry and Pharmacy; 2 Tigray and
Somali; 3Khat: Catha edulis is commonly known as Khat.
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tion [3]. This process is poorly understood, and only a
few of the risk factors involved have been defined.
Therefore detection and management of LTBI in persons
who are at risk is very important. In developed coun-
tries, detection and management of LTBI is a key com-
ponent of TB control [4,5]. In resource-constrained
settings where testing for LTBI is not mandatory, the
World Health Organization (WHO) recommends Iso-
niazid (INH) preventive treatment only for HIV-infected
persons [6] and children < 5 years who are household
contacts of persons with sputum smear-positive pulmon-
ary TB [7]. However, in many cases, this leaves many
MTB-infected people at risk, and there are therefore
efforts to develop TB vaccines targeting the latently-
infected population [8]. This is a long-term goal and in
the meantime efforts are underway to identify those
most at risk for targeted intervention.
For most of the past century, the only immunodiag-
nostic test for LTBI has been the tuberculin skin test
(TST). Its major flaw is its inability to reliably distin-
guish individuals infected with M. tuberculosis from
individuals sensitized to other mycobacteria, including
BCG and most environmental mycobacteria [9]. A dec-
ade ago, interferon-γ release assays (IGRAs) were devel-
oped whereby interferon-γ titers were measured after
in-vitro stimulation of peripheral blood mono-nuclear
cells (PBMC) with antigens such as ESAT-6 and CFP-10
(immunodominant antigens expressed by members of
the M tuberculosis complex, but not by most common
mycobacteria and deleted in the BCG vaccine) [10]. Two
commercial tools are currently available, and have been
widely tested in many clinical situations and compared
with TST, but most of these studies have been conducted
in developed countries [11] with a low incidence of TB
and restricted use of the BCG vaccine, which may com-
promise the specificity of TST since the antigens are
contained in the tuberculin used for TST [9]. Therefore,
the aim of this study was to evaluate the use of the most
commonly-used IGRA, the QuantiFERONW-TB Gold
In-Tube test (QFT-GIT), as compared with TST in the
diagnosis of LTBI in Ethiopia, a country with a high bur-
den of TB and routine BCG vaccination at birth.
Methods
Study participants and study sites
As an exploratory study, a formal power calculation was
not performed, as TST screening is not routinely done in
Ethiopia, and it was unclear what the expected response
rate would be. However, it was known from prior work
[12] that more than half of all healthy adults in the study
region are responsive to ESAT-6 in a standard ELISA
and a substantial proportion would therefore be
expected to make some response in the QFT-GIT andTST. The study participants included were a total of 107
healthy male medical and paramedical students regis-
tered at the Faculty of Medicine, Addis Ababa University
(AAU-MF), Ethiopia, volunteering to participate in a
phase I TB vaccine trial conducted at the Armauer Han-
sen Research Institute (AHRI), Addis Ababa, Ethiopia
(manuscript in preparation). Out of 110 participants
from Addis Ababa University, Medical Faculty, who ful-
filled all of the inclusion and none of the exclusion cri-
teria, one participant did not return for TST reading and
two did not undergo the TST because of withdrawal of
their consent. A total of 107 students (Table 1) were
thus included in the final analysis. All were male and the
mean age was 20.9 (SD= 2.0) years. The mean body
mass index (Kg/m2) was 18.9 (SD= 1.8). The study parti-
cipants were enrolled in the study from December 2008
to February 2009. The general health status of all partici-
pants was assessed based on medical history, physical
examination, chest radiography and blood tests includ-
ing HIV. Exclusion criteria for this study were current or
past history of chronic illness such as diabetes mellitus,
hypertension, renal failure, hematological or other malig-
nancies; clinical or radiological evidence of active tuber-
culosis; use of immune modulating drugs (steroids,
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the 3 months before enrollment in to the study; HIV
seropositivity; and history of previous treatment for TB.
The clinical laboratory tests, hematology, chemistry and
HIV, were performed at the International Clinical La-
boratories (ICL), Addis Ababa, Ethiopia. The QFT-GIT
assay was carried out at the Armauer Hansen Research
Institute (AHRI) laboratory, Ethiopia.
Data collection and blood sample handling
A pretested questionnaire was used in order for the
study physician to collect information on each partici-
pant’s health status and socio-behavioral factors. After
taking medical history and performing physical examin-
ation, a blood sample was collected followed by the TST;
and finally a Chest x-ray was taken. Blood was collected
in QuantiFERONW-TB Gold test tubes (Cellestis Ltd,
Australia) for QuantiFERONW-TB Gold In-Tube (IT)
test; and BD EDTA tubes for HIV test and general labora-
tory test parameters (hematology and chemistry including
blood glucose).
Tuberculin skin test (TST)
Tuberculin (0.1 ml Tuberculin PPD RT 23; Statens
Serum Institute, Copenhagen, Denmark) was injected
intradermally on the ventral aspect of the left forearm.
After 48-72 hours, the transverse diameter of the skin
induration was measured with the ballpoint-pen method
using a plastic ruler graduated in millimeters. A positive
TST result was defined as an induration of ≥10mm [13].
QuantiFERONW-TB gold in-tube (QFT-GIT)
The QuantiFERONW-TB Gold In-Tube (IT) test (Cellestis
Ltd, Australia) was performed according to the manufac-
turer’s instructions. QuantiFERONW-TB Gold IT Analysis
Software was used to analyze raw data and calculate
results which were reported as Negative, Positive and In-
determinate [14].
Statistical analyses
Comparisons were made using Fisher’s exact test, Stu-
dent-t test or Mann–Whitney test where appropriate.
Logistic regression was used to estimate crude and
adjusted odds ratios (OR) to measure the effect of
selected factors on the responses to TST and QFT-GIT
tests. History of contact with TB patient was not
included as a factor in the final analysis as there were
only 4 out of the 107 study participants who identified a
history of contact with a TB patient in their life time.
Concordance between the results of the TST and QFT-
GIT assay was assessed by using Kappa. According to
recommendations regarding the interpretation of Kappa
[15], values of 0.93-1.00 indicate excellent agreement
whereas values of 0.81-0.92 and, 0.61-0.80 indicate verygood and good agreement, respectively. Lower values in-
dicate fair to slight, poor or no agreement. Correlation
between the two LTBI diagnostic tests was assessed by
spearman correlation. STATA statistical software version
8.0 (STATA Corporation, Texas, USA.) was used for data
analysis. All p-values reported are based on two-tailed
comparisons, with statistical significance set at p<0.05.
Ethical considerations
The protocol of this study was approved by AAU-MF,
Ethiopia and the Armauer Hansen Research Institute/All
African Leprosy Rehabilitation and Training Center
(AHRI/ALERT) Institutional Ethical Review Commit-
tees, Ethiopia. Approval was also obtained from the Na-
tional Ethics Review Committee (NERC), Ethiopia. All of
the study participants were provided with all relevant in-
formation about the study before they gave written
consent.
Results
Tuberculin skin test (TST)
Fifty of the 107 participants (46.7%) had a positive TST
result (TST≥10 mm). The mean age (SD) for study parti-
cipants with positive and negative TST results was 21.02
(SD± 1.63) and 20.40 (SD± 1.21) years, respectively
(P<0.05). Forty eight of the 107 study participants
(44.9%, 95%CI: 35.2% to 54.8%) had BCG scar and of
these 26 (54.1%, 95%CI: 39.2% to 68.6%) gave a positive
TST result whereas of the 59 study participants who had
no BCG scar, 24 (40.7%, 95%CI: 28.1% to 54.3%) gave a
positive TST result (p>0.05). Employing a lower TST
cut-off, 54/107 (50.5%, 95%CI: 40.6% to 60.3%) had an
induration of >5mm, and at this cut off too, the impact
of having a BCG scar was not statistically significant.
The median size of induration for TST in participants
with a BCG scar was 10 mm, with a range from 0 to 35
mm and for participants without BCG scar was 0 mm,
with a range from 0 to 25 mm (p>0.05). There were no
significant differences in TST positivity (assessed at
TST≥10 mm) when the groups were analysed by the
other variables listed in Table 2. However, in the logistic
regression analysis (Table 2), the estimated odds of hav-
ing a positive TST result (at a cut-off of ≥10 mm) was
nearly 2 times higher (OR =1.6, 95% CI: 1.11 to 2.20;
p = 0.01) as age increased by one year. Interestingly, ha-
bitual consumption of Catha edulis (a plant commonly
known as Khat and the leaves of which are a mild stimu-
lant) led to a 9 fold increase in risk (OR= 9.2, 95% CI:
1.41 to 59.69, p = 0.02).
QuantiFERONW-TB gold in-tube (QFT-GIT) assay
Forty-seven of the 107 participants (43.9%: 95%CI: 34.3%
to 53.9%) had a positive result in the QFT-GIT assay.
The mean age (SD) for study participants with positive
Table 2 Results of logistic regression for a positive TST
(TST≥10 mm) result
Bivariate analysis Multivariable analysis
Crude OR 95% CI Adjusted OR 95% CI
Age 1.3 1.03-1.68 1.6 1.11-2.20
Nursing/LT 1.5 0.62-3.61 1.1 0.33-3.43
Others1/LT 2.0 0.72-5.30 1.0 0.22-4.81
Second year/First year 0.6 0.28-1.49 0.3 0.08-1.30
Third year/First year 1.1 0.35-3.31 0.5 0.07-3.18
Amhara/AA 0.9 0.26-2.84 1.2 0.24-5.65
Oromia/AA 1.4 0.42-4.60 1.4 0.31-5.92
Southern Nations/AA 0.1 0.01-1.38 0.1 0.01-1.63
Others2/AA 1.4 0.38-4.80 1.0 0.22-4.82
Muslim/Christian 1.2 0.46-3.01 0.7 0.19-2.83
Khat3 consumption
(Yes/No)
2.5 0.58-10.38 9.2 1.41-59.69
BCG Scar (Yes/No) 1.7 0.80-3.72 1.5 0.57-3.82
BMI 1.0 0.79-1.20 0.7 0.54-1 .00
1Midwifery, Radiography, Medicine, Dentistry and Pharmacy; 2Tigray and
Somali; 3Khat: Catha edulis is commonly known as Khat; TST: Tuberculin Skin
Test; LT: Laboratory Technology; AA: Addis Ababa; BMI: Body Mass Index;
OR=Odds Ratio; CI: Confidence Interval.
Table 3 Results of logistic regression for a positive
QFT-GIT assay result
Bivariate analysis Multivariate analysis
Crude OR 95% CI Adjusted OR 95% CI
Age 1.3 1.04-1.69 1.7 1.17-2.35
Nursing/LT 1.9 0.80-4.73 1.4 0.43-4.76
Others1/LT 2.5 0.92-6.94 2.1 0.43-10.10
Second year/First year 0.7 0.28-1.50 0.5 0.11-1.95
Third year/First year 0.9 0.30-2.87 0.8 0.11-5.43
Amhara/AA 1.1 0.33-3.65 1.5 0.30-7.62
Oromia/AA 1.3 0.40-4.47 1.2 0.28-5.60
Southern Nations/AA 0.2 0.02-1.77 0.2 0.02-2.34
others2/AA 1.7 0.48-6.16 1.1 0.22-5.42
Muslim/Christian 1.7 0.67-4.41 1.4 0.36-5.57
Khat3 consumption
(Yes/No)
2.8 0.66-11.77 9.6 1.36-68.13
BCG Scar (Yes/No) 1.3 0.62-2.89 1.0 0.39-2.79
BMI 0.9 0.75-1.16 0.7 0.49-0.91
1Midwifery, Radiography, Medicine, Dentistry and Pharmacy; 2Tigray and
Somali; 3Khat: Catha edulis is commonly known as Khat; QFT-GIT:
QuantiFERONW-TB Gold In-Tube; LT: Laboratory Technology; AA: Addis Ababa;
BMI: Body Mass Index; OR=Odds Ratio; CI: Confidence Interval.
Table 4 Agreement between TST (at two cut-offs) and










BCG scar present ≥10 21 5 0.71 0.000
<10 2 20
BCG scar absent ≥10 23 1 0.93 0.000
<10 1 34
Total ≥10 44 6 0.83 0.000
<10 3 54
BCG scar present >5 22 7 0.67 0.000
<5 1 18
BCG scar absent >5 24 1 0.97 0.000
<5 0 34
Total >5 46 8 0.83 0.000
<5 1 52
TST: Tuberculin Skin Test; QFT-GIT: QuantiFERONW-TB Gold In-Tube;
Pos: Positive; Neg: Negative.
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(SD± 1.15) years, respectively (p<0.05). Forty eight of
107 study participants (44.9%; 95%CI: 35.2% to 54.8%)
had a BCG scar and of these 23 (47.9%; 95%CI: 33.3% to
62.8%) gave a positive QFT-GIT assay result whereas of
the 59 study participants who lacked a BCG scar, 24
(40.7%, 95%CI: 28.1% to 54.3%) gave a positive result
(p>0.05). There were no statistically significant differ-
ences in QFT-GIT assay positivity when analysed for any
of the other variables listed in Table 3. However, in the
logistic regression analysis, the estimated odds of having
a positive QFT-GIT assay results was nearly 2 times
higher (OR= 1.7, 95% CI 1.18-2.35; p =0.004) as age
increased by one year, while Khat consumption was
associated with a 10 fold increase in risk (OR =9.6, 95%
CI 1.36-68.13, p= 0.02).
Agreement between TST and QFT-GIT assay in the
diagnosis of latent TB infection
The overall strength of agreement between TST
(≥10mm) and QFT-GIT assay was very good (Kappa =
0.83, p= 0.000), with concordant results in 98/107
(91.6%, 95%CI: 84.6% to 96.1%). Concordance between
the two tests was good in participants with BCG scar
(85.4%, Kappa = 0.71, p= 0.000), and excellent (96.6%,
Kappa =0.93, p= 0.000) in those who lacked a BCG scar
(Table 4). Out of the 107, 48 (45%) had a TST induration
of 0mm and all were QFT-GIT negative.
At a TST cut-off of >5mm, the overall strength of
agreement between TST and QFT-GIT was also verygood (Kappa = 0.83, p= 0.000), with concordant results
in 98/107 (91.6%). Concordance between the two tests
was also good in participants with BCG scar (83.3%,
Kappa = 0.67, p= 0.000), and was excellent (98.3%,
Kappa = 0.97, p= 0.000) in those who had no BCG scar
(Table 4).
By taking the QFT-GIT assay as the gold standard for
the diagnosis of latent TB infection (because of the
expected higher specificity), we also looked at TST
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tivity at a ≥10mm cut-off was not significantly different
among QFT negative participants with or without a
BCG scar. However, at a TST cut-off of >5mm, among
participants with QFT-GIT negative results, 7 out of 25
(28.0%, 95%CI: 12.1% to 49.4%) participants with BCG
scar were TST positive as compared to 1 out of 35
(2.9%, 0.07% to 14.9%) participants with no BCG scar
(p =0.007).
In addition, the correlation between TST (mm) and
QFT-GIT assay (IU/ml) was assessed and found to be
significant (spearman correlation coefficient = 0.81,
p<0.05) as shown in Figure 1.
Discussion
In this study we evaluated the use of the TST and QFT-
GIT assays in the diagnosis of LTBI in a country with
high burden of TB and routine BCG vaccination at birth.
We observed strong agreement between TST (at a cut-
off of ≥10mm) and the QFT-GIT assay. Our observation
is comparable with a study conducted in a cohort of
health care workers in India [16]. However, a recent
community based study conducted in the Afar region of
Ethiopia by Legesse et al. [17] reported weak agreement
between the two tests.
In our study, all of the study participants were males,
unlike the study by Legesse et al., which reported a higher
prevalence estimate in LTBI in males than females using
TST, but no difference using the QFT assay. Despite this,
the report by Legesse et al. found a lower rate of TST
positivity (36.8%) than that we report here (46.7%). In
addition, although 48% of the participants in the study byFigure 1 Scatter plot of TST measurement and QFT-GIT assay (IU/ml)
Tuberculin PPD RT 23 intradermally on the ventral aspect of the left forearm
measured using a plastic ruler graduated in millimeters. A positive TST resu
In-Tube (QFT-GIT) assay was performed according to the manufacturer’s ins
QuantiFERONW-TB Gold IT Analysis Software and reported as Negative, Pos
latent tuberculosis infection (LTBI) test results, TST in mm and QFT-GIT in IU
coefficient = 0.81, p<0.05.Legesse et al. had a TST induration of 0 mm, compared
with 45% in our study, 42.7% of those were QFT-GIT
positive, compared with 0% in our study. It therefore
appears that the participants in the Afar region study
were more likely to have a weak or absent TST response,
regardless of their QFT status. Factors associated with
TST false-negative reactions may include, but are not lim-
ited to, malnutrition, parasitic infections, HIV/AIDS in-
fection, overwhelming TB disease, or difficulties with
the method of TST administration and interpretation of
the reaction [13]. Any of these factors may be an issue,
as the two populations studied in the two studies are
quite different – relatively affluent, urban and healthy
based on medical history, physical examination, chest
radiography and blood tests including HIV, in this study,
relatively deprived and rural with no in depth evaluation
of their health in the Legesse et al. study. It is therefore
possible that the discordance seen in the study of Legesse
et al. may reflect an increase in false negative TST reac-
tions which could contribute to an under-estimate of the
incidence of LTBI in this population.
The strength of agreement between TST and QFT-GIT
is slightly weaker in BCG vaccinated as compared with
the group without BCG vaccination at both TST cut-offs
(See Table 4). The simplest explanation is the presence of
false positive TST results due to sensitization to the TST
reagent, Purified Protein Derivative (PPD), which contains
mixture of antigens that are common to the MTB complex,
environmental non-tuberculous mycobacterium strain
and BCG [9]. This interpretation is supported by the
stronger effect seen in BCG-vaccinated, QFT-negative
donors at the lower TST cutoff. Some studies have shownresults. Tuberculin skin test (TST) was performed by injecting 0.1 ml
. After 48-72 hours, the transverse diameter of the skin induration was
lt was defined as an induration of ≥10mm. QuantiFERONW-TB Gold
tructions. The QFT-GIT (IU/ml) raw data was analyzed by using
itive and Indeterminate. In this figure, the correlation between the two
/ml, was assessed by spearman correlation; Spearman correlation
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positive TST results [18,19]. Interestingly, however, the
effects (if any) in this study are small: we did not find a
significant difference in TST positivity rate, at cut-offs of
either TST≥10 mm or TST>5 mm, in BCG-vaccinated
and BCG-unvaccinated participants. This finding could
suggest either BCG vaccine administered in infancy has
had a minimal effect on false TST positivity in young
adults, or that the high rate of TST positivity due to true
LTBI resulting from the high incidence of active pulmon-
ary TB in our study setting has over-ridden the effect of
BCG.
The BCG vaccine is not expected to have an effect on
the QFT-GIT assay since the antigens that are contained
in the assay are not present in any BCG strains [20].
Consistent with this, we saw no difference in QFT-GIT
assay positivity rate between the BCG vaccinated (47.9%)
and the non-vaccinated groups (40.7%). This is also con-
sistent with studies elsewhere [21,22], and this might
imply that BCG vaccination at infancy provides limited
protection against MTB infection of adults. In addition
to its specificity, studies have shown that QFT-GIT assay
is as sensitive as TST by correlating its results with the
degree of exposure (duration and proximity) to a source
patient and the likelihood of acquiring infection from
that source [11,22]. Therefore, we used the QFT-GIT
assay as the baseline definition for the diagnosis of LTBI.
Using this approach we were able to see an apparent ef-
fect of BCG vaccination on the TST. Among QFT-GIT
negatives (those thought not to have LTBI), the rate of
TST positivity in participants with a BCG scar was
28.0% (7/25), significantly higher than those without a
scar (1/35 or 2.9%), at cut-off of >5mm. At a cutoff of
≥10mm there was no significant difference. These obser-
vations suggest the effect of BCG vaccine administered
in infancy on TST reactivity in adults is weak. It is de-
tectable at a cut-off of >5mm, but is unlikely to lead to
larger indurations (≥10mm), which are presumably indi-
cative of LTBI. Our hypothesis is in agreement with that
indicated by a meta-analysis of several studies on the ef-
fect of BCG vaccination on TST, which indicated little
effect 15 years after vaccination, especially on TST tests
using the higher cutoff [23]. A more recent meta-
analysis has also shown that the effect of BCG received
in infancy on TST is minimal 10 years after vaccination
[24]. This study confirms those finding and adds the ob-
servation that in countries with a high incidence of TB,
where exposure to infection is likely to be substantial,
does not appear to lead to significant boosting of BCG-
induced PPD sensitivity.
Moreover, we have found a good correlation between
the amount of IFN-γ (IU/ml) in the QFT-GIT assay and
the magnitude of TST induration (mm) (spearman cor-
relation coefficient = 0.81 and P<0.0001), which is alsoconsistent with the hypothesis that LTBI leads to larger
TST induration (Figure 1). This has been suggested by
others as well [25,26].
In highly endemic areas, increasing age is usually asso-
ciated with an increase in the LTBI rate, assessed by
immunodiagnosis [27,28] which is easily explained by
cumulative exposure to MTB with time. However, a new
finding is that in the multivariate analysis, both age in-
crement and Khat (Catha edulis) consumption were
both found to be risk factors for LTBI, based on both
TST (TST≥10 mm) and QFT-GIT assay. Khat is usually
chewed in groups, and this often involves sitting to-
gether in small crowded rooms for long periods of time,
especially in urban settings. In addition, the chewed
leaves are spat out, a process which is likely to efficiently
generate aerosols. If there is one TB patient within the
group the chance of infecting others is probably rela-
tively high. One recent study conducted in Afar region
of Ethiopia where Khat consumption is a common prac-
tice, has also described it as risk factor for the develop-
ment and spread of pulmonary TB [29]. Although
smoking has been associated with LTBI [30-32], the
number of smokers in our study was very low (2 out of
107 study participants) and hence we do not expect it to
confound the effect of Khat consumption even if both
habits are often found in the same individuals. While the
association found here is strong, the small number of
participants who consumed Khat means this finding
cannot be regarded as definitive. Further studies to con-
firm the role for Khat consumption as a risk factor for
LTBI should be conducted as Khat chewing is becoming
a common practice all over the country, and indeed,
throughout the Horn of Africa.
Conclusion
In conclusion, this study showed strong agreement be-
tween TST (TST≥10mm) and QFT-GIT assay in healthy
young adults residing in Ethiopia, a high TB incidence
country, in spite of the routine BCG vaccination at birth
in this population. While there is a possibility of generat-
ing false TST positivity at cut-off of TST > 5mm as the
result of BCG vaccine administered at infancy, it appears
unlikely to affect the diagnosis of LTBI at larger indura-
tions (TST≥10mm).
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